000301573 001__ 301573
000301573 005__ 20250601020822.0
000301573 0247_ $$2doi$$a10.1038/s41392-025-02260-5
000301573 0247_ $$2pmid$$apmid:40414898
000301573 0247_ $$2ISSN$$a2095-9907
000301573 0247_ $$2ISSN$$a2059-3635
000301573 0247_ $$2altmetric$$aaltmetric:177422963
000301573 037__ $$aDKFZ-2025-01081
000301573 041__ $$aEnglish
000301573 082__ $$a610
000301573 1001_ $$0P:(DE-He78)bac8c2c56238485ecf0475ff14438430$$aAhmed, Azaz$$b0$$eFirst author$$udkfz
000301573 245__ $$aDe novo induction of tertiary lymphoid structures: an immunotherapeutic strategy in pancreatic cancer.
000301573 260__ $$aLondon$$bMacmillan Publishers, part of Springer Nature$$c2025
000301573 3367_ $$2DRIVER$$aarticle
000301573 3367_ $$2DataCite$$aOutput Types/Journal article
000301573 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748327801_32432
000301573 3367_ $$2BibTeX$$aARTICLE
000301573 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301573 3367_ $$00$$2EndNote$$aJournal Article
000301573 500__ $$a#EA:D196#LA:D196#
000301573 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000301573 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301573 7001_ $$00000-0003-3843-101X$$aSpringfeld, Christoph$$b1
000301573 7001_ $$0P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aHalama, Niels$$b2$$eLast author$$udkfz
000301573 773__ $$0PERI:(DE-600)2886872-9$$a10.1038/s41392-025-02260-5$$gVol. 10, no. 1, p. 173$$n1$$p173$$tSignal transduction and targeted therapy$$v10$$x2095-9907$$y2025
000301573 909CO $$ooai:inrepo02.dkfz.de:301573$$pVDB
000301573 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bac8c2c56238485ecf0475ff14438430$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301573 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a4053be7ffd6aa9bef69de28753a601$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000301573 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000301573 9141_ $$y2025
000301573 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:44:53Z
000301573 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:44:53Z
000301573 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:44:53Z
000301573 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:44:53Z
000301573 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSIGNAL TRANSDUCT TAR : 2022$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)9930$$2StatID$$aIF >= 30$$bSIGNAL TRANSDUCT TAR : 2022$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-17
000301573 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-17
000301573 9202_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000301573 9201_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000301573 9200_ $$0I:(DE-He78)D196-20160331$$kD196$$lTranslationale Immuntherapie$$x0
000301573 980__ $$ajournal
000301573 980__ $$aVDB
000301573 980__ $$aI:(DE-He78)D196-20160331
000301573 980__ $$aUNRESTRICTED